Literature DB >> 17270614

Recovery of detrusor function after urethral botulinum A toxin injection in patients with idiopathic low detrusor contractility and voiding dysfunction.

Hann-Chorng Kuo1.   

Abstract

OBJECTIVES: To investigate the effect of urethral botulinum A toxin (BoNT-A) injection on idiopathic low detrusor contractility and the correlation of this effect with baseline urodynamic parameters.
METHODS: Twenty-seven patients with idiopathic low detrusor contractility received urethral injection of BoNT-A. Videourodynamic studies were performed at baseline and after treatment. Recovery of detrusor contractility was defined as an increase in detrusor pressure and maximal flow rate and reduced postvoid residual urine volume. The therapeutic results and changes in urodynamic parameters were compared between patients with and without recovery of detrusor contractility.
RESULTS: The recovery of detrusor contractility after urethral BoNT-A injection occurred in 13 patients (48%). Patients with recovery of detrusor contractility had baseline data characterized by normal bladder sensation during bladder filling combined with a poor relaxation or hyperactive urethral sphincter activity. In contrast, patients without recovery of detrusor contractility had poor bladder sensation and a nonrelaxing urethral sphincter. Patients with baseline characteristics of low detrusor contractility combined with poorly relaxed or hyperactive urethral sphincter activity had better results than those with true detrusor underactivity. Of the 13 patients with recovery of detrusor contractility, 5 had a long-term therapeutic effect without the need of repeat urethral injection of BoNT-A for more than 1 year of follow-up.
CONCLUSIONS: Patients with detrusor underactivity with normal bladder sensation combined with a poor relaxation or hyperactive urethral sphincter were significantly more likely to recover normal detrusor function. Neuromodulation of the hyperactive urethral sphincter by urethral BoNT-A is the likely mechanism for this therapeutic effect.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17270614     DOI: 10.1016/j.urology.2006.08.1117

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  16 in total

Review 1.  Updates of underactive bladder: a review of the recent literature.

Authors:  Xing Li; Limin Liao
Journal:  Int Urol Nephrol       Date:  2016-03-01       Impact factor: 2.370

Review 2.  Fowler's syndrome--a cause of unexplained urinary retention in young women?

Authors:  Nadir I Osman; Christopher R Chapple
Journal:  Nat Rev Urol       Date:  2013-12-10       Impact factor: 14.432

Review 3.  Hitting below the belt (bladder): botulinum treatment of urethral and prostate disorders.

Authors:  H Henry Lai; Christopher P Smith
Journal:  Curr Urol Rep       Date:  2007-09       Impact factor: 3.092

Review 4.  Current and potential urological applications of botulinum toxin A.

Authors:  Yuan-Hong Jiang; Chun-Hou Liao; Hann-Chorng Kuo
Journal:  Nat Rev Urol       Date:  2015-08-11       Impact factor: 14.432

5.  Urothelial mucosal signaling and the overactive bladder-ICI-RS 2013.

Authors:  Lori A Birder; Karl-Erik Andersson; Anthony J Kanai; Ann T Hanna-Mitchell; Chris H Fry
Journal:  Neurourol Urodyn       Date:  2014-05-16       Impact factor: 2.696

6.  Dysfunctional voiding: A review of the terminology, presentation, evaluation and management in children and adults.

Authors:  Sanjay Sinha
Journal:  Indian J Urol       Date:  2011-10

Review 7.  Current pharmacological and surgical treatment of underactive bladder.

Authors:  Yuan-Hong Jiang; Cheng-Ling Lee; Jia-Fong Jhang; Hann-Chorng Kuo
Journal:  Ci Ji Yi Xue Za Zhi       Date:  2017 Oct-Dec

8.  Therapeutic Efficacy of Urethral Sphincteric Botulinum Toxin Injections for Female Sphincter Dysfunctions and a Search for Predictive Factors.

Authors:  Yin-Chien Ou; Kuan-Hsun Huang; Hau-Chern Jan; Hann-Chorng Kuo; Yao-Lin Kao; Kuen-Jer Tsai
Journal:  Toxins (Basel)       Date:  2021-06-02       Impact factor: 4.546

9.  OnabotulinumtoxinA Urethral Sphincter Injection as Treatment for Non-neurogenic Voiding Dysfunction - A Randomized, Double-Blind, Placebo-Controlled Study.

Authors:  Yuan-Hong Jiang; Chung-Cheng Wang; Hann-Chorng Kuo
Journal:  Sci Rep       Date:  2016-12-13       Impact factor: 4.379

Review 10.  Underactive bladder: Pathophysiology and clinical significance.

Authors:  Reem Aldamanhori; Nadir I Osman; Christopher R Chapple
Journal:  Asian J Urol       Date:  2017-04-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.